AGM
CLSD

Alpine Global Management’s Clearside Biomedical CLSD Stock Holding History

Alpine Global Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-916
Closed -$38K – 495
2021
Q4 		$38K Buy
+916
New +$59.3K 0.01% 714

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alpine Global Management's CLSD Position: Q1 2022 in Review

Alpine Global Management sold out of Clearside Biomedical (CLSD) in Q1 2022, closing a stake of 916 shares — an estimated $38K sold.

Alpine Global Management first reported a position in CLSD in Q4 2021 and held it in 1 quarter. The position peaked at $38K in Q4 2021. 60 funds tracked by Wall St. Rank hold CLSD as of Q1 2022.

  • Alpine Global Management reported no remaining Clearside Biomedical position as of Q1 2022 after selling out during the quarter.
  • Alpine Global Management sold 916 Clearside Biomedical shares in Q1 2022, an estimated $38K.
  • Alpine Global Management first reported a position in Clearside Biomedical in Q4 2021 and held it in 1 quarter.
  • Alpine Global Management's Clearside Biomedical position peaked at $38K in Q4 2021.
  • 60 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.